Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 466 restricted stock units (RSUs) to two newly-hired employees as of August 31, 2025. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan.
The RSUs will vest over three years, with 33 1/3% vesting annually. Additionally, the RSUs include acceleration provisions in case of a change in control event followed by qualifying employment termination.
Karyopharm Therapeutics (Nasdaq: KPTI), società farmaceutica in fase commerciale specializzata in terapie oncologiche, ha assegnato 466 unità di azioni soggette a restrizioni (RSU) a due nuovi dipendenti alla data del 31 agosto 2025. Le RSU sono state concesse nell'ambito del Piano di Incentivazione Azionaria 2022 della società.
Le RSU matureranno in tre anni, con il 33 1/3% che matura annualmente. Inoltre, le RSU prevedono clausole di accelerazione in caso di cambio di controllo seguito da una cessazione del rapporto di lavoro che soddisfi i requisiti per l'accelerazione.
Karyopharm Therapeutics (Nasdaq: KPTI), una compañía farmacéutica en fase comercial centrada en terapias contra el cáncer, ha otorgado 466 unidades de acciones restringidas (RSU) a dos empleados recientemente contratados con fecha 31 de agosto de 2025. Las RSU se concedieron bajo el Plan de Incentivos en Acciones por Inducción 2022 de la compañía.
Las RSU se harán efectivas en el transcurso de tres años, con un 33 1/3% que se consolida anualmente. Adicionalmente, las RSU incluyen disposiciones de aceleración en caso de un cambio de control seguido de una terminación de empleo que cumpla los requisitos correspondientes.
Karyopharm Therapeutics (Nasdaq: KPTI)는 암 치료제에 주력하는 상업 단계 제약사로, 2025년 8월 31일부로 두 명의 신입 직원에게 466주 제한주식유닛(RSU)을 부여했습니다. 해당 RSU는 회사의 2022년 유인 주식 인센티브 플랜에 따라 지급되었습니다.
이 RSU는 3년에 걸쳐 베스팅(권리확정)되며 매년 33 1/3%가 베스트됩니다. 또한, RSU에는 인수·합병 등 지배구조 변경 후 자격을 갖춘 고용종료가 발생할 경우 권리확정이 가속되는 조항이 포함되어 있습니다.
Karyopharm Therapeutics (Nasdaq: KPTI), une société pharmaceutique en phase commerciale spécialisée dans les traitements contre le cancer, a attribué au 31 août 2025 à deux nouveaux employés 466 unités d'actions restreintes (RSU). Les RSU ont été octroyées dans le cadre du Plan d'incitation en actions 2022 de la société.
Les RSU seront acquises sur trois ans, avec 33 1/3 % qui s'acquièrent chaque année. De plus, les RSU comprennent des dispositions d'accélération en cas de changement de contrôle suivi d'une cessation d'emploi qualifiante.
Karyopharm Therapeutics (Nasdaq: KPTI), ein im kommerziellen Stadium tätiges Pharmaunternehmen mit Schwerpunkt auf Krebsmedikamenten, hat zum 31. August 2025 zwei neu eingestellten Mitarbeitern 466 Restricted Stock Units (RSUs) gewährt. Die RSUs wurden im Rahmen des Aktienanreizplans 2022 des Unternehmens zugewiesen.
Die RSUs werden über drei Jahre vesten, wobei jährlich 33 1/3 % vesten. Zusätzlich enthalten die RSUs Beschleunigungsbestimmungen für den Fall eines Kontrollwechsels, gefolgt von einer berechtigten Beendigung des Arbeitsverhältnisses.
- None.
- None.
Each RSU award will vest over three years, with 33 1/
In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302540131.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
What type of stock awards did Karyopharm Therapeutics (KPTI) grant to new employees?
How do the RSUs vest for Karyopharm's (KPTI) new employees?
What happens to Karyopharm's (KPTI) RSUs in case of a change in control?
Under which plan were Karyopharm's (KPTI) RSU grants made?
